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A B S T R A C T
Objective: To investigate the clinical usefulness of serum cystatin C (Scys) and cystatin 
C-based equations for the screening of chronic kidney disease in primary hypertensive 
patients, and correlate these markers with risk factors for cardiovascular disease. 
Methods: A cross-sectional study was performed in 199 middle-aged adults at a basic health 
unit. Kidney function assessment included measurements of serum creatinine (Scr) and 
Scys levels, 24-hour microalbuminuria (MA), as well as glomerular filtration rate (GFR) 
through Larsson and Modification of Diet in Renal Disease (MDRD) study equations. Bland-
Altman plot analysis was used to calculate the agreement between equations. 
Results: High levels of Scys were found in 22% of the patients, even with normal values of 
GFR estimated by MDRD study equation. Systolic blood pressure and MA correlated better 
with Scys than Scr, but there was no correlation between Scys and diastolic blood pressure. 
Gender, age ≥ 60 years, MA, and uric acid were significantly associated with high Scys levels. 
After multivariate analysis, only age ≥ 60 yrs (RR = 6.4; p < 0.001) and male gender (RR = 3.0; 
p = 0.006) remained associated with high Scys levels. 
Conclusion: Cystatin C can be used as a screening marker both for detecting mild declines of 
renal function and for preventing the risk of cardiovascular events in hypertensive subjects 
with presumably normal renal function.
 ☆Study conducted at Universidade Federal do Maranhão, São Luís, MA, Brazil 
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Cistatina C, função renal e fatores de risco cardiovascular na hipertensão 
primária
R E S U M O
Objetivo: Investigar a utilidade clínica da cistatina C sérica (Scys) e da equação baseada na 
cistatina C na triagem da doença renal crônica em pacientes com hipertensão primária e 
correlacionar esses marcadores com fatores de risco para doença cardiovascular. 
Métodos: Foi realizado um estudo transversal com 199 adultos de meia-idade em uma 
unidade básica de saúde. A avaliação da função renal incluiu medidas dos níveis séricos 
da creatinina (Scr) e Scys, microalbuminúria de 24 h (MA), bem como da taxa de filtração 
glomerular (TFG) por meio das equações de Larsson e do estudo MDRD. Foi utilizada a 
análise Bland-Altman plot para calcular a concordância entre as equações. 
Resultados: Foram encontrados níveis elevados de Scys em 22% dos pacientes, mesmo com 
valores normais da TFG estimada pela equação do estudo MDRD. A pressão sistólica e a 
MA correlacionaram-se melhor com a Scys do que com a Scr, mas não houve correlação 
entre Scys e pressão diastólica. Gênero, idade maior que 60 anos, MA e ácido úrico foram 
significantemente associados com valores elevados de Scys. Após análise multivariada, 
apenas idade maior que 60 anos (RR = 6.4; p < 0.001) e gênero masculino (RR = 3.0; p = 0.006) 
permaneceram associados a níveis aumentados de Scys. 
Conclusão: A cistatina C pode ser utilizada como um marcador de triagem tanto para detectar 
leves declínios da função renal como para prevenir o risco de eventos cardiovasculares em 
sujeitos hipertensos com função renal presumivelmente normal.
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Introduction
Chronic kidney disease (CKD) is a worldwide public health 
problem, and frequently leads to end-stage kidney disease. 
Mild to moderate reductions in kidney function are relatively 
common in hypertensive patients, and are also associated 
with increased risk for cardiovascular events. The detection, 
monitoring, and treatment of CKD are now recognized as 
essential components of risk stratiﬁcation for cardiovascular 
morbidity and mortality in hypertensive patients.1,2
The first step for efficient prevention is early diagnosis, 
but serum creatinine (Scr) is affected by various nonrenal 
factors, particularly muscle mass, and may remain within the 
normal range even with a decrease in glomerular filtration 
rate (GFR) of  ≥ 50%.3 The Modification of Diet in Renal Disease 
(MDRD) study equation is currently recommended because 
it overcomes, at least in part, some of the limitations of 
creatinine measurements.4
Cystatin C has been emerging as a marker of GFR that 
performs better than Scr, and even better than equations based 
on Scr. Similar to Scr, several equations have been elaborated 
to estimate GFR based on serum cystatin C (Scys). However, 
these equations must be vigorously evaluated in large, diverse 
populations and in multiple clinical situations.5,6 Particularly, 
the relation of cystatin C with GFR has not been studied in 
depth in a population of middle-aged adults with near normal 
kidney function.7 Hence, this study aimed to investigate the 
clinical usefulness of Scys and Scys-based equation for the 
screening of decreased renal function in middle-aged adults 
with essential hypertension. Furthermore, the study aimed to 
correlate the Scys values with conventional risk factors for 
cardiovascular disease (CVD).
Methods
A cross-sectional study was performed in 297 patients attending 
the Registration and Monitoring System for Hypertension and 
Diabetes at Primary Care Unit (Sistema de Gestão Clínica da 
Hipertensão Arterial e Diabetes Mellitus da Atenção Básica – 
HiperDia, Brazilian Ministry of Health), between January and 
June 2008. Of the 297 individuals, 199 primary hypertensive 
patients on regular follow-up treatment and without diabetes 
mellitus (DM) were selected for this study. Study design details 
were previously described and published.8,9
Patients were randomly allocated in this study. Exclusion 
criteria were as follows: age < 20 years, pregnancy, inability to 
give informed consent, severe cardiac and renal insufficiency, 
malnutrit ion,  malignancy or  infection,  advanced 
dementia, thyroid dysfunction, use of glucocorticoids, 
and macroalbuminuric stage (urinary albumin excretion 
≥ 300 mg/day). 
The following clinical information was recorded for all 
eligible patients: age, gender, height, weight, duration of 
hypertension, and body mass index (BMI). BMI was calculated 
by dividing body weight in kilograms by the square of height in 
meters. Systolic (SBP) and diastolic (DBP) blood pressures were 
obtained by using a digital sphygmomanometer (Omron®), 
while patients were seated. The average of two blood pressure 
readings was considered.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Serum from whole blood was drawn into BD Vacutainer 
tubes (BD Systems – Basel, Switzerland) from the antecubital 
vein of fasting subjects early in the morning. The serum was 
isolated by centrifugation at 3,500 rpm for 15 min and analyzed 
on the same day. Serum concentrations of biochemical 
parameters were measured using immunoturbidimetry 
(ADVIA 1650, Bayer). Renal function was evaluated through 
the determination of Scr and Scys levels, quantification of 
urinary albumin excretion, and through the estimation of 
GFR based on both Scr and Scys levels. The urinary albumin 
excretion was determined in a 24-h urine sample using 
immunoturbidimetry (ADVIA 1650, Bayer). The urine samples 
were collected on the same day as the serum samples, and 
the patients had been previously instructed on a 24-h urine 
sample collection. Urinary albumin excretion < 30 mg/day was 
classified as normoalbuminuria and between 30-299 mg/day 
as microalbuminuria (MA).
Serum creatinine was measured by kinetic Jaffe method 
(ADVIA 1650, Bayer). Cystatin C was measured through 
a BNA nephelometer that employs a particle-enhanced 
immunonephelometric assay (N Latex Cystatin C, BN 100 
system analyzer – Germany). The reference range of Scys and 
Scr for healthy individuals was reported as 0.53 to 0.95 mg/L 
and ≤ 1.2 mg/dL, respectively.10
Creatinine-based GFR (eGFRcr ) was estimated by the four-
variable MDRD study equation: eGFRcr (mL/min/1.73 m
2) = 
186.3 × (Scr [mg/dL])-1.154 × (age [years])-0.203 × (0.742 if female) 
× (1.210 if African American).11 Cystatin C-based GFR (eGFRcys) 
was estimated using the Larsson formula: eGFRcys (mL/min) = 
77.239 × cystatin C [mg/L]-1.2623.12 The GFR determined by the 
MDRD formula was used as the reference method.4
Statistical analysis was performed using Stata version 10.0. 
Comparisons between quantitative variables were assessed 
using Student’s t-test or Mann-Whitney’s test. Correlation 
analysis was performed using Spearman’s rank test. MedCalc 
for Windows, version 10.4.3.0 (Medcalc Software – Belgium), 
was also used for a Bland-Altman analysis of the GFR 
estimates.13 The limits of agreement are given by the mean 
± 1.96 SD, containing 95% of the values. The mean difference 
(bias) between methods is a measure of accuracy. The SD 
around the mean reflects the dispersion and precision of the 
equations. Statistical significance was inferred when p < 0.05. 
Factors associated with Scys levels >  0.95 mg/L were 
identified using multivariate logistic regression analysis and 
the following were used as independent variables: gender, age 
≥ 60 yrs, SBP > 150 mmHg, DBP > 80 mmHg, hypertriglyceridemia 
(TG  >150 mg/dL), and MA >  30  mg/day (urinary albumin 
excretion [UAE], 30-299 mg/day). The model included variables 
whose univariate analysis showed p < 0.20. Adjustment of the 
model was evaluated by the Hosmer & Lemeshow test. The 
study protocol was approved by the Institutional Review Board 
of the Universidade Federal do Maranhão (Protocol 1977/2007).
Results
A total of 297 hypertensive patients that participated in 
the HiperDia program were evaluated. The final sample 
consisted of 199 hypertensive individuals without DM. 
Table 1 summarizes the clinical characteristics of these 
patients. The study was comprised predominantly of middle-
aged adults with a mean age of 60.6 ± 11.8 years, females 
(73.4%), and overweight patients (27.5 ± 4.8 kg/m2). The subjects 
mean values of Scr and Scys levels were 0.87 ± 0.31 mg/dL and 
0.89 ± 0.25 mg/L, respectively.
Table 1 – Clinical characteristics of the studied patients.
Clinical characteristics n = 199
Age, years 60.6 ± 11.8
Gender (female), % 73.4
BMI, kg/m2 27.5 ± 4.8
SBP, mmHg 149.9 ± 24.2
DBP, mmHg 89.0 ± 12.5
Hypertension duration, years 7.8 ± 7.7
Fasting glucose, mg/dL 78.7± 13.3
Total cholesterol, mg/dL 206.7 ± 41.0
Triglycerides, mg/dL 135.8 ± 68.2
LDL-cholesterol, mg/dL 133.4 ± 34.5
HDL-cholesterol, mg/dL 46.1 ± 11.3
Blood urea nitrogen, mg/dL 30.2 ± 11.07
Uric acid, mg/dL 4.5 ± 1.38
UAE, mg/day (normo/micro), % 86.4 / 13.6
Serum creatinine, mg/dL 0.87 ± 0.31
Serum cystatin C, mg/L 0.89 ± 0.25
eGFRcr, mL/min./1.73 m
2 a 88.1 ± 23.0
eGFRcys, mL/min. 
b 95.9 ± 24.0
Data for continuous variables are mean ± SD and for categorical 
variables are proportions. BMI, body mass index; SBP, systolic  
blood pressure; DBP, diastolic blood pressure; LDL-C, low-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
UAE, urinary albumin excretion; normo, normoalbuminuria; micro, 
microalbuminuria; eGFR, estimated glomerular filtration rate. 
a Based on Modification of Diet in Renal Disease (MDRD) study 
equation; 
b Based on Larsson formula.
The levels of Scys in males were slightly higher than in 
females (0.95 ± 0.21 mg/L vs. 0.86 ± 0.25 mg/L; p = 0.025). 
The mean values of Scys in subjects aged ≥ 60 years were 
significantly higher than those aged < 60 years (0.97 ± 0.29 mg/L 
vs. 0.79 ± 0.13 mg/L; p < 0.001). Likewise, when renal function 
was asessed based on Scr, there was a significant difference 
between males and females (1.04 ± 0.22 mg/dL vs. 0.78 ± 0.31 
mg/dL; p < 0.001). The patients aged ≥ 60 years had higher levels 
of Scr than those aged < 60 years (0.92 ± 0.39 mg/dL vs. 0.78 ± 
0.16 mg/dL; p = 0.002)(Table 2). Of the patients with GFR ≥ 60 
mL/min/1.73 m2 estimated by MDRD equation, 22% presented 
elevated Scys levels (> 0.95 mg/L), while only 3% exceed normal 
values of Scr (>1.2 mg/dL). The same pattern was observed in 
patients with GFR ≥ 60 mL/min/1.73 m2 estimated by Larsson 
formula. The percentage of elevated Scys levels (23%) was 
much higher than for those with elevated Scr levels (4%).
There was a close linear relationship between Scr and Scys 
levels (r = 0.82, p < 0.001). A moderately strong correlation was 
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observed between eGFRcys and eGFRcr (r = 0.61, p < 0.001). 
In order to assess the correlation of different risk factors 
for hypertension with renal function, comparisons with Scr 
and Scys were performed. Scr and Scys levels correlated 
significantly but weakly with age (r = 0.22, p = 0.001 and 
r = 0.37, p < 0.001, respectively), SBP (r = 0.19, p =0.005 and r = 0.28, 
p < 0.001, respectively) and MA (r = 0.31, p < 0.001 and r = 0.38, 
p < 0.001, respectively). The results demonstrated no significant 
correlation between Scys, DBP, and triglycerides. However, 
serum concentrations of uric acid displayed a highly significant 
correlation with Scr and Scys levels (r = 0.50, p < 0.001 and 
r = 0.44, p < 0.001, respectively).
The agreement analysis was calculated according to 
Bland and Altman.13 The mean difference between eGFRcys 
and eGFRcr equations was 8.4 mL/min. The maximum 
value of the mean ± 1.96 SD difference attained +49 and the 
minimum -32.3 (CI 5.3 to 11.3). The precision of the eGFRcys 
in relation to eGFRcr was of 20.72 mL/min/1.73 m2 (Fig. 1). 
After multivariate analysis, only age ≥ 60 years (RR = 6.4; 95% 
CI = 2.84-14.28; p < 0.001) and male gender (RR = 3.0; 95% CI 
= 1.38-6.55; p = 0.006) remained associated with increased 
Scys levels (> 0.95 mg/L).
Discussion
The current study demonstrated that serum cystatin C levels 
had a significant association with conventional risk factors 
for cardiovascular disease and with traditional markers 
of GFR of hypertensive patients in primary health care. In 
accordance with previous studies,14,15 the results showed 
that Scys had a significant correlation with Scr, and that 
the Larsson formula presented a good agreement with the 
commonly used MDRD equation. In spite of this, 22% of the 
patients presented elevated levels of Scys, even with normal 
values of GFR estimated by MDRD equation. This suggests 
that Scys may recognize a certain degree of renal dysfunction 
that was not identified through the determination of Scr 
levels or eGFRcr.
16
As expected, the MDRD study equation showed lower mean 
values of GFR than the Scys-based equation. This observation 
could be explained by the fact that the MDRD equation was 
derived from participants having moderate or severe renal 
failure.11 Herget-Rosenthal et al.17 suggested that a GFR 
calculated with the MDRD equation performs best when the 
GFR ranges between 20 and 60 mL/min. Hence, there are good 
reasons for believing that the MDRD equation underestimates 
GFR and thus overestimates CKD prevalence in subjects with 
near-normal creatinine values. Otherwise, the potential of 
cystatin C and eGFRcys would lie in the recognition of CKD 
stage 2 (GFR 60-90 mL/min.), mainly in patients with low 
muscle mass.17 Furthermore, it has been reported that Scys 
is superior to other markers as a predictor of GFR in primary 
hypertension.18
In this research, the impacts of hypertension on Scys and 
Scr levels were found to be markedly different in subjects 
< 60 and ≥ 60 years of age. Despite weak correlation of the 
variable age with Scys, advanced age (≥ 60 years) was found to 
be an independent predictor of elevated Scys levels. Kottgen 
et al.19 demonstrated a strong and independent association 
of age with Scys concentrations in individuals over 60 
years, even after adjustment for chronic health conditions. 
According to Galteau et al., Scys levels increase slightly in 
Table 2 - Mean levels of serum creatinine (mg/dL) and serum cystatin C (mg/L) according to the variables gender, age 
and glomerular filtration rate (GFR) estimated by the Modification of Diet in Renal Disease (MDRD) study equation.
Variable Serum cystatin C Serum creatinine
(%) Mean ± SD p Mean ± SD p
Gender 0.025 < 0.001
Male (26.6) 0.95 ± 0.21 1.04 ± 0.22
Female (73.4) 0.86 ± 0.25 0.78 ± 0.31
Age < 0.001 0.002
≥60 years (53.6) 0.97 ± 0.29 0.92 ± 0.39
<60 years (46.4) 0.79 ± 0.13 0.78 ± 0.16
eGFRcr
a < 0.001 0.015
≥ 60 years (92.5) 0.84 ± 0.15 0.79 ± 0.16
< 60 years (7.5) 1.38 ± 0.54 1.38 ± 0.11
SD, standard deviation.
aEstimated glomerular filtration rate based on MDRD study equation (mL/min./1.73 m2). 
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Fig. 1 – Agreement analysis.
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males and females above the age of 60 years, probably due to 
physiological aging of renal function.20Although it has been 
reported that Scys is independent of age and gender,5 the 
present results reveal an association between male gender 
and elevated Scys levels. However, this finding might be 
explained by the lower prevalence of men with high mean 
age and, consequently, a mild reduction in GFR level.
The decline of kidney function in older adults is age-
associated, and may represent usual ageing. The ageing of 
the kidney may be explained by cumulative exposure to 
subclinical risk factors and microvascular disease, biochemical 
decrements in kidney cells, loss of nephron units, and 
increased stress on the remaining nephrons over time.7 
Despite the lack of a general agreement defining the lower 
limit of normal GFR in older people, it is known that a decrease 
in GFR is associated with less successful aging.21,22 Recently, it 
has been found that Scys has a better diagnostic performance 
than Scr to predict successful aging.22
In the present study, high Scys levels correlated better with 
SBP than Scr. In contrast, there was no correlation between 
Scys levels and DBP. In the same way, some authors found 
that DBP was negatively23 or not correlated24 with Scys levels, 
whereas SBP showed good correlation with Scys levels.23-25 
Noteworthy, these associations were found in patients 
without clinical CKD by the use of traditional creatinine-based 
methods. This implies that Scys may be an important link 
between kidney function and adequate SBP control.
Interestingly, microalbuminuria had a significantly better 
correlation with cystatin C concentrations than creatinine. 
MA indicates the presence of early signs of atherosclerotic 
vascular damage, serves as marker of severity of hypertension, 
and can predict the development of overt proteinuria and 
cardiovascular events.25 A significant correlation was also 
observed between Scys and serum uric acid, which is also 
known to be closely associated with hypertension, metabolic 
syndrome, cardiovascular risk, and new-onset kidney 
disease.26 Consistent with the present findings, several studies 
have reported a significant correlation of Scys with uric acid,27 
MA, age, and GFR in a hypertensive population.28 It has been 
observed that both Scys and MA are independent risk factors 
for incident CKD stage 3 and could be useful as screening 
tools.29 Moreover, it was displayed that cystatin C-based GFR 
is more sensitive than creatinine-based GFR for predicting MA 
development in the early stage of hypertension.30
In a prospective study involving 4,663 elderly subjects 
with eGFR ≥ 60 mL/min/1.73 m2, Shlipak et al. showed that 
Scys levels ≥ 1.0 mg/L were related to worse cardiovascular 
outcomes, and had a four-fold risk for progressing to CKD 
after four years of follow-up compared with those with 
lower Scys levels.31 Previous studies have also demonstrated 
an association between Scys and several established 
cardiovascular risk factors,32 heart failure,33 coronary events,34 
atherogenic process,35 and death,36 especially in older people. 
Due to this, Scys has been suggested to be not only a marker of 
renal function, but also a marker of metabolic abnormalities, 
inflammation, atherogenesis, and an independent risk factor 
for cardiovascular diseases.27, 37
In contrast to previous reports, Grubb et al.38 have shown 
that inflammatory conditions of a patient do not influence 
the role of Scys as a marker of GFR. Rodondi et al.39 have 
also demonstrated that Scys is not associated with carotid 
atherosclerosis in a population-based random sample of 523 
middle-aged adults. In this setting, increased levels of Scys 
may identify a state of “preclinical” kidney disease, which 
could prevent subsequent development of CKD in patients 
with hypertension and diabetes.40,41 The capacity of Scys to 
early identify an abnormal filtration may explain the fact 
that an increased Scys level indicates higher incidence of 
cardiovascular events and death even with normal GFR.38
There are some limitations to this study. First, GFR was not 
measured with a gold standard method, and thus it was not 
possible to confirm which equation had the best estimate of 
GFR. However, the aim was not to establish the accuracy of 
the equations with a direct measurement of GFR, but rather 
to evaluate the clinical usefulness of cystatin C in primary 
care. Second, the present study’s participants were mostly 
hypertensive women and with mixed ethnicity, which limits 
the generalization of the data. Nevertheless, only a few 
studies have compared Scys- and Scr-based equations for 
the screening of CKD in middle-aged adults with primary 
hypertension in basic health care.
Scys C measurement is being introduced in clinical practice 
around the world. However, despite its clear advantages over 
creatinine as a marker of GFR, cystatin C is still not widely 
used in routine clinical laboratory testing, especially in 
primary care. The major reasons for the lack of incorporation 
of cystatin C into daily clinical practice have been its higher 
reagent cost, the absence of standardized measurement 
procedures, and the need for further validation in large 
populations.
In public health, cystatin C can be used as a reliable marker 
for both detecting early kidney dysfunction and preventing the 
risk of cardiovascular morbimortality. Regardless of whether 
mildly reduced renal function represents pathology or normal 
ageing in older adults, adequate screening and follow-up are 
needed. In addition, cystatin C may provide new insights into 
the importance of the relationship between kidney disease 
and hypertension in subjects with presumably normal renal 
function.
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